Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 7/20 | 0.70 |
| ▸ | CDK2 | P24941 | 7/20 | 0.70 |
| ▸ | MAPT | P10636 | 6/20 | 0.70 |
| ▸ | NPC1 | O15118 | 4/20 | 0.70 |
| ▸ | RAB9A | P51151 | 4/20 | 0.70 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.70 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.70 |
| ▸ | GSK3B | P49841 | 2/20 | 0.70 |
| ▸ | GSK3A | P49840 | 1/20 | 0.70 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13534527 | 0.88 | ALDH1A1 (0.73) | CCNA2CDK2MAPTNPC1RAB9A | |
| SCHEMBL7753436 | 0.86 | CCNA2 (0.76) | CCNA2CDK2MAPTNPC1RAB9A | |
| SCHEMBL7757552 | 0.86 | CCNA2 (0.76) | CCNA2CDK2MAPTNPC1RAB9A | |
| SCHEMBL1250529 | 0.84 | NPC1 (0.72) | CCNA2CDK2MAPTNPC1RAB9A | |
| SCHEMBL3234050 | 0.82 | CDK2 (0.62) | CCNA2CDK2MAPTNPC1RAB9A | |
| SCHEMBL1248419 | 0.82 | CCNA2 (1.00) | CCNA2CDK2MAPTNPC1RAB9A | |
| SCHEMBL4468574 | 0.81 | NPC1 (0.72) | CCNA2CDK2MAPTNPC1RAB9A | |
| SCHEMBL7753445 | 0.80 | MAPT (0.61) | CCNA2CDK2MAPTNPC1RAB9A | |
| SCHEMBL13534522 | 0.80 | CDK2 (0.60) | CCNA2CDK2MAPTNPC1RAB9A | |
| SCHEMBL4558262 | 0.80 | MAPT (0.67) | CCNA2CDK2MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010039275-A1 | Use of 2,4-diaminothiazole derivatives | NOVO NORDISK A/S (DK) | 2001-11-08 | — | — | US | disclosed |
| WO-2001056567-A1 | 2,4-DIAMINOTHIAZOLE DERIVATIVES AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 (GSK-3) INHIBITORS | NOVO NORDISK A/S (DK) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039275-A1 | Use of 2,4-diaminothiazole derivatives | GSK3A, GSK3B, GSKIP | CCNA2 3738/4885CDK2 566/4885MAPT 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.